Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis

INTRODUCTION: Patients with relapsed or refractory malignancies have a poor prognosis. Immunotherapy with chimeric antigen receptor T (CAR-T) cells redirects a patient’s immune cells against the tumour antigen. CAR-T cell therapy has demonstrated promise in treating patients with several haematologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Grigor, Emma J M, Fergusson, Dean A, Haggar, Fatima, Kekre, Natasha, Atkins, Harold, Shorr, Risa, Holt, Robert A, Hutton, Brian, Ramsay, Tim, Seftel, Matthew, Jonker, Derek, Daugaard, Mads, Thavorn, Kednapa, Presseau, Justin, Lalu, Manoj M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988064/
https://www.ncbi.nlm.nih.gov/pubmed/29288188
http://dx.doi.org/10.1136/bmjopen-2017-019321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988064/
https://www.ncbi.nlm.nih.gov/pubmed/29288188
http://dx.doi.org/10.1136/bmjopen-2017-019321

Ejemplares similares